Varenicline

Drug Profile

Varenicline

Alternative Names: Champix; Chantix; CP-526,555; CP-526555-18; Varenicline tartrate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class 3-ring heterocyclic compounds; Azabicyclo compounds; Benzazepines; Bridged-ring heterocyclic compounds; Quinoxalines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Smoking withdrawal
  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Feb 2017 Pfizer has patent protection for varenicline in European Union, Japan and USA (Pfizer Form 10-K, February 2017)
  • 01 Jan 2017 Pfizer completes a phase III trial in Smoking withdrawal in Pakistan (PO) (ISRCTN94103375)
  • 16 Dec 2016 US FDA approves removal of boxed warning regarding serious neuropsychiatric events from varenicline label
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top